Yahoo
    HKSE - Delayed Quote HKD

    Simcere Pharmaceutical Group Limited (2096.HK)

    10.180 +0.160 (+1.60%)
    At close: 4:08:07 PM GMT+8
    Loading Chart for 2096.HK
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint

    Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
    PR Newswire 1d ago
    Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint

    Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding Product Commercialization Footprint
    PR Newswire 1d ago
    Simcere Pharmaceutical Group (SEHK:2096) Stock Looks Undervalued At Today’s Price

    Simcere Pharmaceutical Group (SEHK:2096) Stock Looks Undervalued At Today’s Price
    Simply Wall St. 15d ago
    Simcere and Stanford partner to develop IPF therapies

    Simcere and Stanford partner to develop IPF therapies
    Pharmaceutical Technology 4mo ago
    Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis

    Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
    PR Newswire 4mo ago
    Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development

    Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
    PR Newswire 2mo ago
    NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

    NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026
    GlobeNewswire 5mo ago
    NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers

    NextCure and Simcere Zaiming Initiate Dose Optimization for SIM0505 (CDH6 ADC) in Gynecologic Cancers
    GlobeNewswire 5mo ago
    NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026

    NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
    GlobeNewswire 6mo ago
    Asian Stocks With Estimated Discounts Up To 44.4% Offering Investment Opportunities

    Asian Stocks With Estimated Discounts Up To 44.4% Offering Investment Opportunities
    Simply Wall St. 9mo ago
    Asian Market's Top Value Stocks Estimated Below Intrinsic Worth January 2026

    Asian Market's Top Value Stocks Estimated Below Intrinsic Worth January 2026
    Simply Wall St. 9mo ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: